---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-116264"
form_type: "8-K"
ticker: "TELA"
cik: "0001561921"
company_name: "TELA Bio, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:40:57.438303+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# TELA Bio Q3 revenue $15.1M (+35% YoY); narrows FY2023 guidance to $57-60M

## Summary
- Revenue of $15.1M, up 35% YoY, marking 11th straight quarter of ≥35% growth.
- OviTex hernia mesh now #1 biologic mesh in U.S. by unit volume.
- OviTex PRS revenue grew 46% YoY; commercial launch of Long-Term Resorbable variant.
- Q3 net loss $11.0M vs. $10.7M a year ago; cash $58.2M at quarter end.
- Updated FY2023 revenue guidance to $57-60M (38-45% YoY growth).

## SEC filing metadata
- accession: 0001104659-23-116264
- form_type: 8-K
- ticker: TELA
- cik: 0001561921
- company_name: TELA Bio, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1561921/000110465923116264/0001104659-23-116264-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1561921/000110465923116264/tm2330287d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-116264
- JSON: https://secwatch.observer/filing/0001104659-23-116264.json
- Plain text: https://secwatch.observer/filing/0001104659-23-116264.txt

## Key facts
- Earnings Releases
  TELA Bio, Inc. reported third quarter ended September 30, 2023 results: revenue $15.1 million, net income $11.0 million. Guidance reaffirmed.
  - Period: third quarter ended September 30, 2023
  - Revenue: $15.1 million
  - Net income: $11.0 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: the preservation and restoration of the patient's own anatomy, today reported financial results for the third quarter ended September 30, 2023. Recent Highlights · Revenue of $15.1 million in the third quarter, representing growth of 35% over the third quarter of 2022 – the 11th consecutive quarter of 35% or greater year-over-year growth; · Demand for OviTex® and
  evidence_url: https://www.sec.gov/Archives/edgar/data/1561921/000110465923116264/0001104659-23-116264-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.